A Phase 1, Open-label, Multicenter Study to Determine the Pharmacokinetics and Safety of Intravenous Eravacycline in Children With Suspected or Confirmed Bacterial Infection
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Eravacycline (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Tetraphase Pharmaceuticals
- 18 Jul 2019 Planned End Date changed from 17 Oct 2019 to 17 Nov 2020.
- 18 Jul 2019 Planned primary completion date changed from 27 Jun 2019 to 27 Aug 2020.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.